Small molecule splicing modulators that disrupt O-GlcNAc homeostasis
Open Access
- 12 January 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
O-Linked N-acetylglucosamine (O-GlcNAc) is a nucleocytoplasmic post-translational modification that is tightly regulated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Dysregulation of O-GlcNAc in human disease has motivated efforts to therapeutically modulate O-GlcNAc. Drug repurposing efforts can accelerate these campaigns and unveil how clinically relevant compounds and pathways intersect with O-GlcNAc. Here we report the results of three parallel drug repurposing screens against the O-GlcNAc cycling enzymes in cells and in vitro that reveal kinase inhibitors GSK690693 and Y-33075 act as splicing modulators that disrupt O-GlcNAc homeostasis and simultaneously downregulate OGT and OGA. These effects are independent of their respective annotated targets, AKT and ROCK, and are distinct from OGT and OGA inhibitors and similar kinase inhibitors. Evaluation of a panel of splicing modulators revealed three additional potent compounds (OTS964, indisulam, GNF2133) that similarly downregulate OGT and OGA with distinct splicing profiles. These findings reveal previously unobserved splicing modulator chemotypes and approaches to disrupt O-GlcNAc homeostasis.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (1RF1AG081475)
- U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (AI153175, CA242115)
This publication has 68 references indexed in Scilit:
- Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- Genome-Wide CRISPR Screening to Identify Mammalian Factors that Regulate Intron Retention2022
- Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteersAlzheimer's & Dementia, 2021
- Predicting Splicing from Primary Sequence with Deep LearningCell, 2019
- A Conserved Splicing Silencer Dynamically Regulates O-GlcNAc Transferase Intron Retention and O-GlcNAc HomeostasisCell Reports, 2017
- RNA Helicases DDX5 and DDX17 Dynamically Orchestrate Transcription, miRNA, and Splicing Programs in Cell DifferentiationCell Reports, 2014
- A quantitative high-throughput screen identifies potential epigenetic modulators of gene expressionAnalytical Biochemistry, 2008
- (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- Parkinson's disease: pathological mechanisms and actions of piribedilJournal of Neurology, 1992